News

Janssen Research & Development, LLC (Janssen) Phase 3 data presented for the first time at Digestive Disease Week® 2016 showed that a significantly greater proportion of adult patients with moderate to severe Crohn's disease receiving STELARA®(ustekinumab) subcutaneous (SC) maintenance...

US guidelines now recommend Entresto as standard of care for HFrEF as an alternative to ACEs or ARBs; call for doctors to switch patients with mild to moderate symptoms to Entresto Updated guidelines from the European Society of...

Merck, a leading science and technology company, today announced that it signed a letter of intent on innovation and digitalization in Africa with the GIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit) yesterday evening.   This followed a...

Chugai Pharmaceutical Co Ltd announced that the results of the Japanese phase III study (J-ALEX) of Alecensa®, in ALK fusion gene positive NSCLC patients, will be presented at the annual meeting of the ASCO which will be held June...

Osaka University and Chugai Pharmaceutical Co Ltd announced the conclusion of a comprehensive collaboration agreement for advanced research in immunology between the Osaka University Immunology Frontier Research Center (IFReC) and Chugai. IFReC was selected for the...

First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna®both in front-line and second-line following Glivec®* First genomic analysis and 3-year efficacy/safety update for Tafinlar® + Mekinist® combination in BRAF V600E/K-mutant advanced melanoma,...

Valeant Pharmaceuticals International, Inc. announced that Mr. Joseph Papa, Chairman and Chief Executive Officer, will participate at the UBS Global Healthcare Conference to be held at the Grand Hyatt Hotel in New York City on Monday, May 23, 2016...